Research Signal – Source date 2021-02-11
ClinicalTrials.gov gives this afatinib study a broad title about “solid tumors” with NRG1 gene fusions, while its condition field names non-squamous non-small-cell lung cancer. NRG1 fusion describes an altered joining of genes within a tumor. The difference raises a useful question: what patient group does the record describe, and how would it judge whether treatment was working?
The registry describes an observational study comparing people treated with afatinib (Gilotrif) with people who received another systemic therapy. Its current record reports 110 participants enrolled. That figure is the total actual enrollment, not a response count or a result for either treatment group. Although the named condition points to a lung cancer type, the available record description does not establish that every participant had that cancer.
The registry uses two ways to record tumor response
The study listed objective response rate, or ORR, using two methods. One relied on the response recorded by a physician in a patient’s chart. The other used measurements of tumor lesions and the standard RECIST 1.1 criteria. Both approaches count the share of patients whose cancer had a complete or partial response, at an initial assessment and at the best recorded response.
A complete response means the target lesions have disappeared, or that all non-target lesions have disappeared. A partial response means the measured target lesions have shrunk by at least 30% compared with their baseline size. These definitions describe how response would be classified; they are not a finding that any particular share of participants responded.
The chart-based measure reflects what physicians recorded in routine care. The lesion-based measure instead applies a stated size threshold to tumor measurements. Comparing the two can help explain what the registry intended to count, but the evidence supplied here gives no group-specific rates to compare.
The other outcomes follow disease over time
A response at one assessment does not describe how long it lasted. Duration of response tracks the time from an initial complete or partial response until progression or death. Duration of clinical benefit begins with an initial complete response, partial response, or stable disease, and follows the same kinds of events. The second measure therefore includes people whose disease initially stayed stable, even if it did not shrink enough to count as a partial response.
Progression-free survival follows time from the start of a treatment line until progression or death. Time to progression follows the time until treatment is stopped because of progression. Overall survival, by contrast, follows time from any therapy in the metastatic setting until death. These measures answer different questions: whether disease worsened, whether a response or stable period endured, and how long people lived after treatment began.
Time on treatment is another listed outcome. It runs from the start of a treatment line until treatment ends for any reason, so it can include discontinuation unrelated to cancer progression. For several measures, the record describes censoring people who were still receiving treatment or stopped for another reason at their last treatment or visit date. In practical terms, those observations contribute information up to that point, but they do not count as a recorded progression or death after it.
Safety is part of weighing treatment
The registry also listed the number of patients who experienced an adverse drug reaction during the treatment line being studied. It defined an adverse drug reaction as a harmful, unintended response to a medicine where a causal relationship is at least reasonably possible. That is a medicine-related category, not simply any event that occurred during treatment.
Response, disease control, survival, and harms belong in the same assessment because a treatment choice involves more than whether tumors shrink. The supplied catalog identifies this safety outcome but gives no count for either group, so it cannot show how often such reactions occurred or how they compared between treatments.
What the record can and cannot tell us
This was an observational comparison, based on treatment people received in practice rather than a record described here as randomly assigning them to afatinib or another therapy. The groups could therefore differ in ways that influence their outcomes. The study’s design and outcome definitions alone cannot show that afatinib caused better results.
The dates also matter. The registry posting date associated with this source is 11 February 2021. The current record separately reports that the study actually started on 15 October 2020, reached primary completion on 20 December 2021, and completed on that same date. It currently marks results as posted. Those later record details should not be read as information established by the February 2021 posting.
The evidence catalog available for this article contains outcome definitions and study details, but no group-specific response rates, survival estimates, adverse-reaction counts, or treatment-effect estimate. That limits what can be said here about the comparison: the listed measures explain what the study assessed, but the supplied material cannot rank the treatments.
What clearer evidence could mean for treatment choices
Clinicians caring for people whose tumors carry an NRG1 fusion could have a sounder basis for choosing among systemic therapies if comparable evidence shows which option offers durable disease control with acceptable harms. This registry’s comparison could contribute to that understanding, but the treatment choice would depend on what the results establish about both benefit and risk.
Key Sources
- Primary source: Assessment of Real-World Outcomes Associated With Afatinib (Gilotrif) Use in Patients With Solid Tumors Harboring NRG1 Gene Fusions
Government or Regulator · Clinical Trial · 2021-02-11
Keep exploring